Exenatide
GLP-1 receptor agonist · Byetta and Bydureon. Availability has reduced; check current UK supply
- UK status
- MHRA licensed
- Availability
- Prescription only
- Evidence base
- Human RCT, phase 3
- Controlled drug
- No
Sequence
39 amino acids. A synthetic version of exendin-4, found in Gila monster saliva.
The short version
What it does
Controls blood sugar in type 2 diabetes, and causes some weight loss along the way.
How it does it
A copy of a chemical found in the saliva of a venomous American lizard, which happens to act on the same fullness signal your own gut uses. The lizard version lasts far longer in the body than the human one, which is what made a usable drug possible.
The catch
It is the original, and it has largely been left behind. Twice-daily injections and a smaller effect than the newer drugs mean new prescriptions have mostly moved on.
Everything below goes into the detail, with sources.
Every drug in this class traces back to a lizard. In the 1990s researchers found that a compound in the saliva of the Gila monster acted on the human GLP-1 receptor and lasted hours rather than minutes. Exenatide is the synthetic version of that compound, and it is where all of this started.
At a glance
- Compound type
- Peptide, 39 amino acids
- Drug class
- GLP-1 receptor agonist
- Derived from
- Exendin-4, in the saliva of the Gila monster
- Route
- Injection under the skin
- Frequency
- Twice daily (Byetta) or weekly (Bydureon)
- First approved
- 2005 in the US, the first drug of its class
- UK licence
- Type 2 diabetes. No weight-management licence.
- In sport
- Not currently on the WADA Prohibited List. Verify with UKAD.
01What it is
Human GLP-1 is destroyed within about two minutes of release, which is why it was useless as a drug. Exendin-4, from the saliva of the Gila monster, binds the same receptor and resists the enzyme that breaks GLP-1 down. That resistance is the whole reason the class exists.
Exenatide is synthetic exendin-4. Approved in the US in 2005 as Byetta, twice daily, and later reformulated as Bydureon, a weekly version using microspheres to release the drug slowly.
It is a good corrective to the idea that these drugs are unnatural interventions in appetite. The mechanism they use is one your gut already runs after every meal. What the lizard supplied was a version that survives long enough to be a medicine.
02How it came about
Exendin-4 was characterised in Gila monster venom in the early 1990s. Development followed, and Byetta was approved by the FDA in 2005, the first GLP-1 receptor agonist anywhere. The weekly Bydureon formulation followed.
Liraglutide arrived in 2009 lasting about a day, semaglutide in 2018 lasting a week, and tirzepatide in 2022 acting on two receptors. Each generation displaced the last, and exenatide has been progressively left behind. UK availability of these brands has reduced.
03UK legal and licensing status
Exenatide is licensed in the UK for the treatment of type 2 diabetes. It has no weight-management licence, the same position as dulaglutide.
Availability of these brands has reduced as prescribing moved to newer agents, and discontinuation decisions in this class have been made market by market. If you are on it or considering it, your pharmacist will know the current position better than any website.
04How it works
The same GLP-1 receptor mechanism as the rest of the class: glucose-dependent insulin release, slowed gastric emptying, reduced appetite signalling. The twice-daily formulation produces peaks around meals; the weekly one produces steadier levels.
05What it is not
Claims that attach themselves to this compound and do not hold up.
- Not licensed for weight management in the UK, the same position as dulaglutide.
- Not the drug people mean by a weight-loss jab. It is the ancestor of those drugs, not one of them.
- Not a class effect guarantee. The EXSCEL trial did not show the cardiovascular benefit later drugs in this class reported, which is a useful caution against assuming findings transfer.
06What the evidence shows
The AMIGO trials established glycaemic control and supported approval. EXSCEL examined cardiovascular outcomes in type 2 diabetes and did not demonstrate a significant benefit, which is worth recording because later drugs in the class did.
That difference matters. It shows the cardiovascular benefits reported for semaglutide and others are not automatically a class effect that every GLP-1 drug shares.
Contemporary head-to-head data against the current generation is limited, because attention moved on. Long-term outcome data exists but in a population treated to older standards.
07Reported harms
Gastrointestinal effects predominate, as across the class. Injection site nodules were a recognised issue with the weekly microsphere formulation specifically. The SPC carries the full frequency table.
The January 2026 MHRA drug safety alert on acute pancreatitis applies to GLP-1 medicines as a class.
08Interactions and cautions
Class cautions apply: additional contraception alongside the pill, telling your anaesthetist before surgery, and raised low blood sugar risk in combination with insulin or sulfonylureas. Slowed gastric emptying may affect absorption of oral medicines, and with a twice-daily drug taken before meals the timing question is more prominent than with a weekly one.
09Stopping
Glucose control worsens and any weight effect reverses. For type 2 diabetes this is a treatment change for a prescriber to manage.
10Monitoring
HbA1c, weight, kidney function and tolerability, as part of routine diabetes review.
11Questions worth asking
Take these to a doctor or pharmacist. A good clinician will not mind being asked, and the answers are specific to you in a way nothing on this page can be.
- Is there a reason for this rather than a newer drug in the same class?
- Is supply of this brand secure where I get my prescriptions?
- If weight is part of what I am hoping for, is there a licensed option instead?
12Common questions
Is exenatide really made from lizard venom?
The drug is synthetic, made in a laboratory. It is a copy of exendin-4, a compound found in the saliva of the Gila monster, which is where the discovery came from. No lizards are involved in manufacturing.
Is Byetta still available in the UK?
It is a licensed UK medicine, but availability of these brands has reduced as prescribing moved to newer agents, and this class has seen market-by-market discontinuations. Ask your pharmacist for the current position.
Why would anyone take it instead of Ozempic?
Very few new prescriptions do. Reasons would be cost, local availability, or being established on it and doing well. It is a licensed medicine with a twenty-year track record, not a bad drug.
Does it have cardiovascular benefits like semaglutide?
The EXSCEL trial did not demonstrate a significant cardiovascular benefit. That is a useful reminder that findings for one drug in this class do not automatically apply to all of them.
13Sources
Links go to the authoritative source. Where a document sits behind a paywall or moves around, the full citation is given so you can find it yourself.
- Summary of Product Characteristicselectronic medicines compendium
- Exenatide monographBNF
- EXSCEL cardiovascular outcomes trialPubMed
- Exendin-4 discovery literaturePubMed
- Drug Safety Update on GLP-1 medicinesMHRA, January 2026
Already taking this?
Guides for people already on it
Side effects and what is expected, what to do when weight loss slows, moving up a dose, supply problems, eating enough, and stopping. Written for the situation you are actually in rather than the decision you already made.
Get told when something changes
A short email when a licence changes, a safety alert lands, or a trial reports. No selling, no advertising, no sharing your address. Unsubscribe whenever.
14Change history
Every substantive change to this record is logged here with its date. Corrections are made openly, not quietly.
Loading…
Want telling when this record changes? Follow it from your account.